Strasbourg, France, December 2, 2025 – We’re excited to announce the addition of Sascha Hartmann, Director of Business Development, and Thomas Flower, Business Development Manager for the UK, Nordics, Austria, and Germany, as we strengthen our footprint across these key regions.
This milestone marks the formation of our dedicated team in the UK, Nordics, Austria, and Germany — bringing us closer to our partners and enabling more responsive, collaborative approaches to early-stage drug discovery. With direct access to our highly experienced scientists in DNA-Encoded Libraries, fragment-based screening, medicinal and synthetic chemistry, biophysics, structural biology, and in vitro/in vivo pharmacology, we are ready to deliver cutting-edge expertise where it matters most.
As part of our global growth strategy, these new roles will deepen relationships with biotech and pharma innovators. Sascha and Thomas bring outstanding experience and proven success in business development and scientific leadership, ensuring impactful partnerships across these territories.
We’re thrilled to welcome them aboard — this is just the beginning of an exciting journey!
Sascha Hartmann
Sascha is a seasoned life-sciences business development leader with a career rooted in chemistry, pharmaceutical R&D, and strategic commercial growth. With more than two decades supporting biotech and pharma partners across Europe, he is known for translating complex scientific capabilities into clear, actionable value for clients.
Sascha has built a strong reputation for forming collaborative, long-term partnerships and guiding organisations from early discovery through to development. His scientific background allows him to engage credibly with technical teams, while his commercial expertise helps shape tailored solutions that accelerate pipelines and strengthen project outcomes.
Prior to joining Novalix, Sascha held various positions across the life-sciences industry, including roles in business development, technical sales, client management at drug discovery and development CROs such as Symeres, Concept Life Sciences, Peakdale Molecular, Selcia, as well as hands-on R&D positions at MSD and Sanofi — working in medicinal chemistry and isotopic labelling.
In senior business development roles, Sascha has played a key part in expanding service portfolios, enhancing market visibility, and supporting the growth of contract research and development organisations. He is recognised for his consultative style — listening closely to client needs, ensuring seamless communication between R&D and commercial teams, and championing a culture of transparency, quality, and scientific excellence.
With experience spanning both lab-based research and customer-facing leadership, Sascha brings a rare blend of technical insight and strategic vision. A natural relationship builder, he connects easily with stakeholders at all levels and thrives in environments driven by innovation and scientific problem-solving.
Based in the UK, Sascha remains committed to advancing the European biotech and drug-discovery landscape.
Thomas Flower
Thomas Flower recently stepped into the role of Business Development Manager at Novalix, after more than two years of experience within Novalix. During this time, Thomas led Protein Science and served as Senior Project Manager for Structural Biology, where he managed complex projects and guided scientific teams. His transition into business development reflects a unique combination of scientific depth and strategic vision.
Before joining Novalix, Thomas held senior scientific positions at Galapagos and completed postdoctoral research at the University of California, Berkeley. He also spent four years at the Francis Crick Institute in London, advancing structural biology research. Academically, Thomas carried out his PhD research in Structural Biology at the Francis Crick Institute and the certification was awarded by University College London. He also earned a BSc in Biochemistry from Cardiff University, laying a strong foundation for his expertise in drug discovery.
Thomas brings a wealth of technical knowledge, including structural biology, X-ray crystallography, biophysics, protein expression and purification, and AI-driven structure determination using tools like AlphaFold. His skills in scientific communication and medical writing complement his ability to foster collaborations that bridge science and business.
With this background, Thomas is well-positioned to strengthen partnerships across the UK, Nordics, Austria, and Germany.